Cargando…
Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
OBJECTIVE: This study evaluated the characteristics of new users of sodium glucose co-transporter 2 inhibitors (SGLT2i) in clinical practice to assess the applicability of the findings from clinical trials (Empagliflozin, Cardiovascular Outcomes and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) tr...
Autores principales: | Shao, Shih-Chieh, Lin, Yi-Han, Chang, Kai-Cheng, Chan, Yuk-Ying, Hung, Ming-Jui, Kao Yang, Yea-Huei, Lai, Edward Chia-Cheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954814/ https://www.ncbi.nlm.nih.gov/pubmed/32043472 http://dx.doi.org/10.1136/bmjdrc-2019-000742 |
Ejemplares similares
-
Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study
por: Shao, Shih-Chieh, et al.
Publicado: (2019) -
Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
por: Shao, Shih-Chieh, et al.
Publicado: (2020) -
Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier’s gangrene
por: Yang, Jeff Yufeng, et al.
Publicado: (2020) -
Dementia and vagotomy in Taiwan: a population-based cohort study
por: Lin, Shih-Yi, et al.
Publicado: (2018) -
Nationwide trends in the epidemiology of diabetic foot complications and lower-extremity amputation over an 8-year period
por: Lin, Cheng-Wei, et al.
Publicado: (2019)